Page last updated: 2024-10-24

retinal cone cell apoptotic process

Definition

Target type: biologicalprocess

Any apoptotic process in a retinal cone cell, one of the two photoreceptor cell types of the vertebrate retina. [CL:0000573, GOC:jc]

Retinal cone cell apoptosis is a tightly regulated process that eliminates damaged or unwanted cone photoreceptor cells, ensuring the proper functioning of the retina. The process is initiated by a variety of intrinsic and extrinsic signals, including DNA damage, oxidative stress, and the activation of death receptors. These signals trigger a cascade of molecular events that ultimately lead to the dismantling of the cell.

**Key steps in the apoptotic process:**

1. **Signal transduction:**
* **Intrinsic pathway:** Mitochondria play a central role in this pathway. Damage to the cone cell can lead to the release of cytochrome c from the mitochondria into the cytoplasm. This triggers the activation of caspase-9, a key apoptotic protease.
* **Extrinsic pathway:** Activation of death receptors on the cell surface by external signals triggers the activation of caspase-8, another apoptotic protease.

2. **Caspase activation:** Caspase activation is a central event in apoptosis. These proteases are responsible for cleaving and activating downstream substrates, ultimately leading to the dismantling of the cell.

3. **DNA fragmentation:** Apoptotic cells exhibit characteristic DNA fragmentation. Endonucleases are activated that cleave DNA between nucleosomes, resulting in DNA ladders visible on electrophoresis.

4. **Cell shrinkage:** The cell shrinks and condenses, accompanied by changes in the cell membrane.

5. **Formation of apoptotic bodies:** The cell breaks down into small membrane-bound vesicles called apoptotic bodies that are phagocytosed by neighboring cells or macrophages, preventing inflammation.

**Factors that influence cone cell apoptosis:**

* **Age:** Cone cells, like other retinal cells, are susceptible to age-related changes, including apoptosis.
* **Light exposure:** Excessive light exposure can induce oxidative stress and contribute to cone cell death.
* **Genetic factors:** Genetic mutations can predispose individuals to retinal degeneration and cone cell loss.
* **Disease conditions:** Diseases like retinitis pigmentosa and macular degeneration involve significant cone cell death.

**Consequences of cone cell apoptosis:**

* **Vision loss:** The loss of cone cells leads to a decrease in visual acuity, color vision, and contrast sensitivity.
* **Retinal degeneration:** In severe cases, widespread cone cell apoptosis can contribute to retinal degeneration and blindness.

Understanding the molecular mechanisms underlying cone cell apoptosis is crucial for developing therapies that protect these vital cells and prevent vision loss.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Thyroid hormone receptor betaA thyroid hormone receptor beta that is encoded in the genome of human. [PRO:DNx, UniProtKB:P10828]Homo sapiens (human)

Compounds (17)

CompoundDefinitionClassesRoles
amiodaroneamiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.

Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound
cardiovascular drug
3,3',5-triiodothyroacetic acidtiratricol : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)acetic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxy-3-iodophenoxy group. It is a thyroid hormone analogue that has been used in the treatment of thyroid hormone resistance syndrome.
3,3',5-triiodothyropropionic acidaromatic ether
thyroxinethyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.

Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine;
thyroxine zwitterion
antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
triiodothyronine3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.

Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine
human metabolite;
mouse metabolite;
thyroid hormone
mifepristoneMifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.3-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound
abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
tetraiodothyroacetic acid3,3',5,5'-tetraiodothyroacetic acid : A monocarboxylic acid that is thyroacetic acid carrying four iodo substituents at positions 3, 3', 5 and 5'.

tetraiodothyroacetic acid: RN given refers to parent cpd; structure
2-halophenol;
aromatic ether;
iodophenol;
monocarboxylic acid
apoptosis inducer;
human metabolite;
thyroid hormone
3,5-dimethyl-3'-isopropyl-l-thyronine3,5-dimethyl-3'-isopropyl-L-thyronine: RN given refers to (L)-isomer
pregna-4,17-diene-3,16-dionepregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor3-hydroxy steroidandrogen
gc 1 compoundGC 1 compound: structure in first sourcediarylmethane
kb 141KB 141: an anticholesteremic agent; structure in first source
kb 130015KB 130015: structure in first source
cgs 23425CGS 23425: structure given in first source
3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid: a thyroid receptor beta1 agonist; structure in first source
kb 21153-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid: a thyroid hormone receptor agonist with anticholesteremic activity
fg-4592roxadustat : An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid. It is an inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH).

roxadustat: structure in first source
aromatic ether;
isoquinolines;
N-acylglycine
EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor
mgl-3196resmetirom: a thyroid hormone receptor-beta agonist